AMOXICILLIN AND CLAVULANATE POTASSIUM tablet, film coated

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

有效成分:

AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9), CLAVULANATE POTASSIUM (UNII: Q42OMW3AT8) (CLAVULANIC ACID - UNII:23521W1S24)

可用日期:

DirectRx

给药途径:

ORAL

处方类型:

PRESCRIPTION DRUG

疗效迹象:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin and clavulanate potassium tablets, oral suspension and chewable tablets are a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below: 1.1 Lower Respiratory Tract Infections Caused by beta-lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis. 1.2 Acute Bacterial O

授权状态:

Abbreviated New Drug Application

产品特点

AMOXICILLIN AND CLAVULANATE POTASSIUM- AMOXICILLIN AND CLAVULANATE
POTASSIUM TABLET, FILM COATED
DIRECTRX
----------
AMOXICILLIN/CLAV POT
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
amoxicillin and clavulanate potassium and other antibacterial drugs,
amoxicillin and
clavulanate potassium should be used only to treat infections that are
proven or
strongly suspected to be caused by susceptible bacteria. When culture
and
susceptibility information are available, they should be considered in
selecting or
modifying antibacterial therapy. In the absence of such data, local
epidemiology and
susceptibility patterns may contribute to the empiric selection of
therapy.
Amoxicillin and clavulanate potassium tablets, oral suspension and
chewable tablets are
a combination penicillin-class antibacterial and beta-lactamase
inhibitor indicated in the
treatment of infections due to susceptible isolates of the designated
bacteria in the
conditions listed below:
1.1 Lower Respiratory Tract Infections
Caused by beta-lactamase–producing isolates of Haemophilus
influenzae and Moraxella
catarrhalis.
1.2 Acute Bacterial Otitis Media
Caused by beta-lactamase–producing isolates of H.influenzae and
M.catarrhalis.
1.3 Sinusitis
Caused by beta-lactamase–producing isolates of H.influenzae and
M.catarrhalis.
1.4 Skin and Skin Structure Infections
Caused by beta-lactamase producing isolates of Staphylococcus aureus,
Escherichia
coli, and Klebsiella species.
1.5 Urinary Tract Infections
Caused by beta-lactamase producing isolates of E.coli, Klebsiella
species, and
Enterobacter species.
1.6 Limitations of Use
When susceptibility test results show susceptibility to amoxicillin,
indicating no beta-
lactamase production, amoxicillin and clavulanate potassium should not
be used.
Amoxicillin and clavulanate potassium may be taken without regard to
meals; however,
absorption of clavulanate potassium is enhanced when amoxicillin and
clavulanate
potassium is administered at the start of a meal. To minimize